$

SIBE

$

Über uns

$

Mission/Leitbild

$

Geschichte

$

Team

$

Forschungsschwerpunkte

$

Publikationen

$

Presse

$

Stellen bei der SIBE

$

Standorte

$

Rechtliches

$

Impressum

$

Datenschutzerklärung

$

Business Performance

$

Business Projects

$

Innovation Projects

$

Scientififc Projects

$

Projektbeispiele

$

Personal

$

Rekrutierung

$

Mitarbeiterbindung

$

Employer Branding

$

Persönlichkeitsentwicklung

$

Partner

$

School

$

Programme

$

M.Sc. International Management – SIBE-Management-Master

$

German-US-Dual-Degree (M.Sc./MBA)

$

M.Sc. in Digital Leadership

$

Diploma of Perfomance and Leadership

$

LL.M. in International Business Law

$

Doctor of Business Administration (DBA)

$

Erfahrungsberichte

$

Lehre

$

Mitglieder

$

Systemakkreditierung

$

Qualität

$

Partnerhochschulen

$

Studierende & Alumni

$

Mentoring

$

Für Gründer

$

Benefits & Netzwerke

$

Empfehlungsprämien

$

E-Campus

$

Stellenangebote

$

Projektbeispiele

$

Downloads

$

FAQ

Relapsed and refractory multiple myeloma: oral or intravenous therapy?

2. November 2021
Redaktion SIBE

Relapsed and refractory multiple myeloma is a cancer that originates in plasma cells of the bone marrow and is generally considered to be incurable. In recent years, various combination therapies have been approved for this disease, which can prolong the life expectancy of those affected. While most medications are administered intravenously, to date there is only one oral form of administration.

As a recent study by the WifOR Institute and Takeda Pharma Vertrieb GmbH & Co. KG with the assistance of SIBE Professor Dr. Dennis Ostwald was able to show, oral therapies have a cost advantage over intravenous treatments. The financial impact is mainly due to the level of drug prices and the duration of therapy.

Read the full article in the renowned journal “The European Journal of Health Economics“.

Ähnliche Beiträge

All the best to our new graduates

The two-year course has been completed and the SIBE Management Master (SMM21-205), German-US Dual Degree (MScMBA21-205) and SIBE Digitalization Master (MScDL02b) courses have successfully passed the SIBE-Management-Master – M.Sc. International Management,...

read more

All the best to our new graduates

The two-year course has been completed and the SIBE Management Master (SMM21-204), German-US Dual Degree (MScMBA21-204) and SIBE Digitalization Master (MScDL02a) courses have successfully passed the SIBE-Management-Master – M.Sc. International Management,...

read more